Detalles de la búsqueda
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
3.
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
Ann Hematol
; 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38805036
4.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
5.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
6.
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Ann Hematol
; 99(12): 2903-2909, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32583088
7.
Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.
Biol Blood Marrow Transplant
; 20(7): 1026-32, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699116
8.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38849344
9.
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
Target Oncol
; 18(6): 885-892, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37747623
10.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666982
11.
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Front Oncol
; 12: 1026251, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36457484
12.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35924160
13.
Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Biol Blood Marrow Transplant
; 16(7): 1018-24, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20172040
14.
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Hematol Oncol
; 28(4): 202-8, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21136583
15.
Low-dose rituximab in adult patients with primary immune thrombocytopenia.
Eur J Haematol
; 85(4): 329-34, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20546023
16.
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Eur J Haematol
; 84(3): 223-8, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19930441
17.
Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Hematol Oncol
; 27(1): 40-5, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19206083
18.
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Hematol Oncol
; 27(4): 198-202, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19475701
19.
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Ann Hematol
; 88(2): 151-8, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18709502
20.
Clinically useful prognostic factors in acute myeloid leukemia.
Crit Rev Oncol Hematol
; 66(3): 181-93, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17996460